Manejo de la dermatitis atópica con Dupilumab en pacientes adolescentes

Abstract

Atopic dermatitis is a dermatological disease characterized by inflammation and skin irritation with a chronic, recurrent course, leading to outbreaks or skin eruptions. Adolescents represent one of the most vulnerable population groups. Treatment includes lifestyle changes, typical corticosteroid usage, and other drugs such as Dupilumab. Objective: To describe the management of atopic dermatitis with Dupilumab in adolescent patients. Methodology: This study is a literature review, approached under a descriptive-explanatory design, considering the following sources of information: ScienceDirect, PubMed, Scopus, LILACS, Cochrane, Redalyc, SciELO, and ProQuest. Results: Dupilumab significantly reduces the intensity and spread of atopic dermatitis, controlling cutaneous remission and the spread of pruritus, critical aspects of improving the quality of life of adolescents without compromising their physical, cognitive, and psychosocial development. Adverse effects include respiratory problems, angioedema, fever, general body discomfort, joint pain, skin rashes, inflammation of lymph nodes, and allergic reactions in the area where the drug was injected. Conclusion: Dupilumab is a drug that enables improvement at the cutaneous level, reduces the intensity of clinical manifestations associated with the disease, and enhances the patient's quality of life.